Table 2. Adverse events and laboratory abnormalities.
| Event or abnormality | n (%) |
| Any adverse events | 141 (100.0) |
| Severe adverse events* | 5 (3.5) |
| Adverse events leading to discontinuation# | 1 (0.0) |
| Adverse events in ≥10% of patients | |
| Anemia | 76 (53.9) |
| Fever | 53 (37.6) |
| Fatigue | 52 (36.9) |
| Headache | 31 (22.0) |
| Dizziness | 28 (19.9) |
| Anorexia | 26 (18.4) |
| Diarrhea | 25 (17.7) |
| Flu-like symptoms | 25 (17.7) |
| Hypertriglyceridemia | 21 (14.9) |
| Erythra | 17 (12.1) |
| Urinary tract infection | 16 (11.34) |
| Nausea | 13 (19.5) |
| Laboratory abnormalities in ≥10% of patients | |
| Leukopenia | 118 (83.7) |
| Neutropenia | 103 (73.1) |
| Thrombocytopenia | 51 (36.2) |
| Lymphocytosis | 26 (14.2) |
| High ALT | 24 (17.0) |
| Hypochromia | 22 (16.3) |
| High AST | 19 (13.5) |
| Erythropenia | 19 (13.5) |
*
One severe adverse event of the pegylated-interferon and ritonavir regimen, but not the ritonavir-boosted danoprevir regimen, and three severe adverse events not related to treatment regimen.
#
One car crash death was not related with treatment and the patient was excluded from the study.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.